Comparative Risk Of Adverse Outcomes Associated With Nonselective And Selective Antimuscarinic Medic

Among older adults with dementia and overactive bladder (OAB) using nonselective and selective antimuscarinics, researchers conducted this retrospective cohort study to investigate the comparative risk of falls/fractures and all‐cause hospitalizations. The primary exposure was categorized as nonselective (oxybutynin, tolterodine, trospium, and fesoterodine) and selective (solifenacin and darifenacin). The study cohort comprised of 13,896 (76.9%) nonselective and 4,179 (23.1%) selective antimuscarinic incident users. Data revealed that the unadjusted falls/fractures rate was 27.14% (3,772) for nonselective and 24.55% (1,026) for selective users. The authors found no differential risk of falls/fractures and all‐cause hospitalizations in older adults with dementia and OAB using nonselective and selective antimuscarinics. Further research is required to understand the role of pharmacodynamics and pharmacokinetics in the safety profile of antimuscarinics in dementia.

​

Source